Eli Lilly Has a Major Problem With Its Weight Loss Drugs Zepbound and Mounjaro
Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent quarterly sales.
This Pharma Stock Is Rising. The Weight-Loss Drugs Race Has Widened Beyond Lilly, Novo.
Viking says an early-stage study of its obesity pill VK2735 showed adults on the highest dosage lost 8.2% of their body weight in four weeks.
Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up
Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster weight loss drug Zepbound was not dragging down sales. Pfizer sales rose 31% to $17.
Eli Lilly plans to begin advertising weight-loss drug Zepbound
Eli Lilly ( LLY) is planning to advertise its blockbuster weight loss drug, Zepbound, for the first time next month. Despite investor and industry recognition of the branded GLP-1 drug, "unaided awareness of Zepbound ... is actually not very high," CEO David Ricks said on an earnings call Wednesday morning.
Lilly cuts outlook on surprising weight-loss drug disappointment
Eli Lilly and Co. lowered its full-year guidance Wednesday on lackluster sales of its blockbuster weight-loss drug, a shocking miss for a drugmaker that had been going from strength to strength on insatiable demand for these drugs.
Knockoff weight loss drugs are having a moment. Eli Lilly isn't worried
CEO David Ricks said the sale of cheaper, off-brand versions of the company’s blockbuster weight loss drug isn’t having a “financial impact” on the pharma giant.
Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs
These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates appetite and digestion. The medications control blood sugar and help people eat less,
Are Diabetes Drugs Really Safe (& Reliable) for Weight Loss?
There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight loss. Whether you have type 2 diabetes or obesity, you may have heard about medications like Ozempic® that can help manage blood sugar levels and weight.
Viking Therapeutics stock jumps after ‘great’ trial of weight-loss drug
Viking Therapeutics stock rose in early trade on Monday as the company showed its oral weight-loss drug in clinical trials was successful.
This Pharma Stock Is Soaring 21%. The Weight-Loss Drugs Race Has Widened Beyond Lilly, Novo.
Viking said that an early-stage study of its obesity pill VK2735 showed adults on the highest dosage lost 8.2% of their body weight in four weeks.
Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data
Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.
Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not ...
Reuters9d
Eli Lilly gets nod to launch weight-loss drug in Hong Kong - Bloomberg News
Oct 27 (Reuters) - Eli Lilly (LLY.N), opens new tab expects to start selling its weight-loss drug in Hong Kong as ...
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
As Race To Best 'Miracle' Obesity Drug Heats Up, Ozempic Maker Novo Nordisk Tests New Hybrid Drug That Can Reduce Weight Up To 25%
Novo's development chief, Martin Holst Lange, has shown optimism about the drug's promise, though he refrained from making ...
Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...
Eli Lilly Earnings Have Wall Street Asking New Questions About GLP-1 Drugs. Is Something Going Wrong?
One big idea has loomed over healthcare stocks over the past two years: Demand for the new GLP-1 weight loss medicines from ...